Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Monoclonal Antibodies Strike Back: New Data on Their Use in COVID-19
  • CME
  • MOC
  • CE

Loading...
Listen to Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss exciting new data on the use of monoclonal antibodies for the treatment and prevention of COVID-19.
Arthur Kim, MD
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s)
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: September 9, 2021 Expiration: September 8, 2022

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:

  • Rationale for use of mAb
  • Potential for resistance to mAb
  • Single vs combination therapy with mAb
  • Challenges in implementation of mAb as treatment or prevention
  • Bamlanivimab
  • Sotrovimab
  • Casirivimab plus imdevimab

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify new data on the use of monoclonal antibodies in the management of COVID-19 that warrant prompt integration into patient care
  • Appropriately advise patients and colleagues regarding evolving best practices in the use of monoclonal antibodies for treatment of COVID-19

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Arthur Kim, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.
Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, Immunocore, Vaxxinity, and ViiV Healthcare.

Staff

Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who provide care for patients with or at risk of COVID-19.

Goal

The goal of this activity is to enable healthcare professionals to adopt optimal evidence-based strategies for COVID-19 management in an efficient and timely manner through expert screening and interpretation of the evolving scientific literature.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-172-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 09, 2021, through September 08, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Clinical Care Options’ (CCO) commentary from Dr. Paul E. Sax on promising studies of a repurposed drug, fluvoxamine, for treatment of COVID-19

Paul E. Sax, MD Released: September 21, 2021

Clinical Care Options’ (CCO) commentary from Dr. Vikramjit Mukherjee on the association between surges in COVID-19 caseload and mortality.

Vikramjit Mukherjee, MD Released: September 3, 2021

Downloadable slides from CCO on the rationale and evidence supporting timeliness in the administration of therapies that act directly against SARS-CoV-2

Arthur Kim, MD Lynora Saxinger, MD, FRCPC, CTropMed Released: August 25, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue